开能健康(300272) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 372,040,366.05, representing a 10.79% increase compared to CNY 335,819,450.56 in the same period last year[5] - Net profit attributable to shareholders was CNY 16,605,727.28, up 4.28% from CNY 15,924,291.20 year-on-year[5] - The company reported a basic earnings per share of CNY 0.0296, which is a 5.34% increase from CNY 0.0281 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 372,040,366.05, an increase of 10.5% compared to CNY 335,819,450.56 in Q1 2022[24] - Net profit for Q1 2023 was CNY 17,525,658.71, a decrease of 11.3% from CNY 19,769,782.43 in Q1 2022[25] - The total comprehensive income for the first quarter of 2023 was CNY 16,760,127.96, compared to CNY 20,079,828.01 in the same period last year, reflecting a decrease of approximately 16.4%[26] Cash Flow - The net cash flow from operating activities reached CNY 53,035,355.56, a significant increase of 1,988.09% compared to a negative cash flow of CNY -2,808,939.15 in the previous year[5] - The net cash flow from financing activities was CNY 78,892,355.95, a dramatic increase of 3,835.14% compared to CNY 2,004,818.58 in the previous year[9] - The total cash inflow from operating activities was CNY 397,018,358.38, slightly down from CNY 405,228,257.23 in the previous year, reflecting a decrease of 2.9%[27] - The company generated CNY 388,070,676.86 in cash from sales of goods and services, an increase from CNY 381,649,254.79 in the same quarter last year, showing a growth of 1.1%[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,358,072,021.45, reflecting a 1.90% increase from CNY 2,314,014,391.36 at the end of the previous year[5] - Current liabilities rose to CNY 933,181,345.32 in Q1 2023, compared to CNY 897,329,240.01 in Q1 2022, indicating an increase of 4.0%[23] - The company reported a decrease in total liabilities to CNY 1,223,828,412.91 in Q1 2023 from CNY 1,196,530,910.78 in Q1 2022, a decline of 2.3%[23] - The total equity attributable to shareholders increased to CNY 1,106,206,777.37 in Q1 2023, up from CNY 1,090,276,172.70 in Q1 2022, representing a growth of 1.5%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,343[11] - The largest shareholder, Qu Jianguo, holds 33.72% of the shares, totaling 194,638,209 shares[11] - The top ten shareholders collectively hold 146,539,043 restricted shares, with Qu Jianguo having 145,978,657 shares locked up[14] - The company has a total of 15,467,120 shares held in repurchase accounts among the top ten shareholders[12] - The total number of shares held by the top ten unrestricted shareholders is 48,659,552 shares for Qu Jianguo[11] - The total number of shares held by the top ten shareholders is significant, indicating concentrated ownership[11] Share Repurchase and Convertible Bonds - The company plans to repurchase shares using a maximum of 5,000,000 yuan, with a repurchase price not exceeding 7.4 yuan per share, potentially acquiring approximately 675,675.6 shares, or 1.17% of total equity[16] - The company has adjusted the maximum repurchase price from 7.5 yuan to 7.4 yuan per share following a cash dividend distribution of 0.1 yuan per share[16] - The company repurchased a total of 5,467,100 shares at an average price of 6.05 yuan per share, utilizing 31,367,162 yuan, which represents approximately 0.947% of the company's total shares[17] - As of March 31, 2023, the company held 15,467,120 shares in its repurchase account, accounting for about 2.68% of the total share capital[17] - The company plans to issue convertible bonds to unspecified investors, with an expected fundraising amount not exceeding 250 million yuan[18] - The convertible bonds will have a face value of 100 yuan each and a term of six years from the date of issuance[18] - The company’s board of directors approved the issuance of convertible bonds, which was subsequently ratified by the shareholders' meeting[18] Expenses - Financial expenses rose by 248.47% to CNY 11,570,325.35, mainly due to foreign exchange losses and increased interest expenses[8] - Research and development expenses for Q1 2023 were CNY 14,635,763.55, compared to CNY 13,260,879.81 in Q1 2022, marking an increase of 10.4%[25] - The company reported a decrease in tax expenses by 36.58% to CNY 3,039,107.74, attributed to a decline in profits[8] Inventory and Receivables - Accounts receivable decreased from 228,995,604.19 yuan at the beginning of the year to 205,737,316.04 yuan by the end of March 2023[21] - Inventory decreased from 322,242,963.51 yuan at the beginning of the year to 286,353,697.49 yuan by March 31, 2023[21]